JP2025081477A5 - - Google Patents
Info
- Publication number
- JP2025081477A5 JP2025081477A5 JP2025023976A JP2025023976A JP2025081477A5 JP 2025081477 A5 JP2025081477 A5 JP 2025081477A5 JP 2025023976 A JP2025023976 A JP 2025023976A JP 2025023976 A JP2025023976 A JP 2025023976A JP 2025081477 A5 JP2025081477 A5 JP 2025081477A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- seq
- composition
- cdrs
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163226118P | 2021-07-27 | 2021-07-27 | |
| US63/226,118 | 2021-07-27 | ||
| JP2022119632A JP7638935B2 (ja) | 2021-07-27 | 2022-07-27 | 抗ｃｃｒ８抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022119632A Division JP7638935B2 (ja) | 2021-07-27 | 2022-07-27 | 抗ｃｃｒ８抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025081477A JP2025081477A (ja) | 2025-05-27 |
| JP2025081477A5 true JP2025081477A5 (https=) | 2025-10-16 |
Family
ID=82898810
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022119632A Active JP7638935B2 (ja) | 2021-07-27 | 2022-07-27 | 抗ｃｃｒ８抗体 |
| JP2025023976A Pending JP2025081477A (ja) | 2021-07-27 | 2025-02-18 | 抗ｃｃｒ８抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022119632A Active JP7638935B2 (ja) | 2021-07-27 | 2022-07-27 | 抗ｃｃｒ８抗体 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US11639393B2 (https=) |
| EP (2) | EP4491635A3 (https=) |
| JP (2) | JP7638935B2 (https=) |
| KR (2) | KR20250135339A (https=) |
| CN (1) | CN117425677A (https=) |
| AR (1) | AR126578A1 (https=) |
| AU (1) | AU2022317803A1 (https=) |
| BR (1) | BR112023024837A2 (https=) |
| CA (1) | CA3220121A1 (https=) |
| CO (1) | CO2023015915A2 (https=) |
| DK (1) | DK4214240T3 (https=) |
| ES (1) | ES2995868T3 (https=) |
| FI (1) | FI4214240T3 (https=) |
| HR (1) | HRP20241561T1 (https=) |
| HU (1) | HUE069018T2 (https=) |
| IL (2) | IL319478A (https=) |
| LT (1) | LT4214240T (https=) |
| MX (1) | MX2023014154A (https=) |
| PL (1) | PL4214240T3 (https=) |
| PT (1) | PT4214240T (https=) |
| RS (1) | RS66234B1 (https=) |
| SA (1) | SA523451582B1 (https=) |
| SI (1) | SI4214240T1 (https=) |
| SM (1) | SMT202400483T1 (https=) |
| WO (1) | WO2023010054A1 (https=) |
| ZA (1) | ZA202309516B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| CN120076829A (zh) | 2022-10-18 | 2025-05-30 | 明治制果药业株式会社 | T细胞肿瘤的治疗剂 |
| EP4661869A1 (en) | 2023-02-06 | 2025-12-17 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators |
| JPWO2024248037A1 (https=) | 2023-05-30 | 2024-12-05 | ||
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025186043A1 (en) | 2024-03-06 | 2025-09-12 | Bayer Aktiengesellschaft | Pharmaceutical formulation for anti-ccr8 antibodies |
| WO2025259871A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| US10087259B1 (en) | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
| EP4092045A1 (en) | 2016-05-16 | 2022-11-23 | Checkmab S.R.L. | Markers selectively deregulated in tumor-infiltrating regulatory t cells |
| WO2018112032A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8 |
| ES2863412T3 (es) | 2017-03-29 | 2021-10-11 | Shionogi & Co | Composición farmacéutica para el tratamiento del cáncer |
| WO2020138489A1 (ja) * | 2018-12-27 | 2020-07-02 | 塩野義製薬株式会社 | 新規抗ｃｃｒ８抗体 |
| CA3160204A1 (en) | 2020-01-06 | 2021-07-15 | Vaccinex, Inc. | Anti-ccr8 antibodies and uses thereof |
| TWI890283B (zh) * | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| US20250019449A1 (en) | 2020-03-05 | 2025-01-16 | Memorial Sloan Kettering Cancer Center | Anti-ccr8 agents |
| AU2021244200A1 (en) | 2020-03-23 | 2022-11-24 | Bristol-Myers Squibb Company | Anti-CCR8 antibodies for treating cancer |
| TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| WO2022003156A1 (en) | 2020-07-02 | 2022-01-06 | Oncurious Nv | Ccr8 non-blocking binders |
| EP4186926A4 (en) | 2020-08-28 | 2024-06-05 | Harbour Biomed US, Inc. | ANTI-CCR8 ANTIBODIES AND CORRESPONDING APPLICATION |
| CA3198456A1 (en) | 2020-10-14 | 2022-04-21 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
| EP4010378B1 (en) | 2020-10-16 | 2026-05-06 | LaNova Medicines Limited | Anti-ccr8 monoclonal antibodies and uses thereof |
| CA3206124A1 (en) | 2020-12-24 | 2022-06-30 | Vib Vzw | Non-blocking human ccr8 binders |
| WO2022136647A1 (en) | 2020-12-24 | 2022-06-30 | Oncurious Nv | Human ccr8 binders |
-
2022
- 2022-07-27 FI FIEP22754752.8T patent/FI4214240T3/fi active
- 2022-07-27 US US17/815,505 patent/US11639393B2/en active Active
- 2022-07-27 HU HUE22754752A patent/HUE069018T2/hu unknown
- 2022-07-27 LT LTEPPCT/US2022/074214T patent/LT4214240T/lt unknown
- 2022-07-27 DK DK22754752.8T patent/DK4214240T3/da active
- 2022-07-27 EP EP24198142.2A patent/EP4491635A3/en active Pending
- 2022-07-27 PT PT227547528T patent/PT4214240T/pt unknown
- 2022-07-27 SM SM20240483T patent/SMT202400483T1/it unknown
- 2022-07-27 JP JP2022119632A patent/JP7638935B2/ja active Active
- 2022-07-27 RS RS20241306A patent/RS66234B1/sr unknown
- 2022-07-27 BR BR112023024837A patent/BR112023024837A2/pt active Search and Examination
- 2022-07-27 CN CN202280040102.9A patent/CN117425677A/zh active Pending
- 2022-07-27 MX MX2023014154A patent/MX2023014154A/es unknown
- 2022-07-27 PL PL22754752.8T patent/PL4214240T3/pl unknown
- 2022-07-27 KR KR1020257028953A patent/KR20250135339A/ko active Pending
- 2022-07-27 WO PCT/US2022/074214 patent/WO2023010054A1/en not_active Ceased
- 2022-07-27 AU AU2022317803A patent/AU2022317803A1/en active Pending
- 2022-07-27 IL IL319478A patent/IL319478A/en unknown
- 2022-07-27 EP EP22754752.8A patent/EP4214240B1/en active Active
- 2022-07-27 CA CA3220121A patent/CA3220121A1/en active Pending
- 2022-07-27 IL IL307533A patent/IL307533B2/en unknown
- 2022-07-27 AR ARP220101985A patent/AR126578A1/es unknown
- 2022-07-27 HR HRP20241561TT patent/HRP20241561T1/hr unknown
- 2022-07-27 SI SI202230078T patent/SI4214240T1/sl unknown
- 2022-07-27 ES ES22754752T patent/ES2995868T3/es active Active
- 2022-07-27 KR KR1020237041895A patent/KR102860769B1/ko active Active
-
2023
- 2023-10-11 ZA ZA2023/09516A patent/ZA202309516B/en unknown
- 2023-11-19 SA SA523451582A patent/SA523451582B1/ar unknown
- 2023-11-22 CO CONC2023/0015915A patent/CO2023015915A2/es unknown
-
2025
- 2025-02-18 JP JP2025023976A patent/JP2025081477A/ja active Pending